Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

C. Landolfo; T. Bourne; Wouter Froyman; Ben Van Calster; Jolien Ceusters; A. C. Testa; Laure Wynants; P. Sladkevicius; C. Van Holsbeke; Ekaterini Domali; Robert Fruscio; E. Epstein; D. Franchi; Marek Kudła; Valentina Chiappa; Juan Luis Alcázar; F. Leone; F. Buonomo; Maria Elisabetta Coccia; S. Guerriero; Nandita Deo; L. Jokubkiene; L. Savelli; D. Fischerová; Artur Czekierdowski; J. Kaijser; An Coosemans; Giovanni Scambia; Ignace Vergote; D. Timmerman; L. Valentin

doi:10.1002/uog.26080

Abstract

A large proportion of adnexal masses can be classified as benign by the modified BDs. For the remaining masses, the ADNEX model can be used to estimate the risk of malignancy. This two-step strategy is convenient for clinical use.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Landolfo et al. (2022) studied this question.

synapsesocial.com/papers/69deacb24838c5c0bab0cba7 https://doi.org/10.1002/uog.26080

View Full Paper

Ask AI

Bookmark

Share

Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

Abstract

Discussion

Cite This Study

Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

Abstract

Discussion

Cite This Study

Keep reading

Keep reading